Biomarker Panel May Help Predict Gestational Diabetes Early in Pregnancy
Researchers may have identified an effective way of detecting gestational diabetes mellitus (GDM) earlier in pregnancy.
Researchers may have identified an effective way of detecting gestational diabetes mellitus (GDM) earlier in pregnancy.
BioReference Laboratories, Inc. has acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
This proprietary test is a multi-analyte protein biomarker assay which is designed to be run from a simple blood draw.
The Foresight carrier screen identified 45% more couples at risk for having a child with cystic fibrosis than current guideline-based testing.
Read MoreA novel multiplexing platform called ‘high definition polymerase chain reaction’ brings together widely used, low-cost chemistries and qPCR instrumentation with proprietary data science algorithms to enable streamlined multiplex test development and very affordable test deliverables.
Read MoreThe Parsortix system offers the potential to extend NIPT to a wide range of conditions not feasible with existing techniques.
Read MoreStatisticians used data from more than a million Panorama tests to devise an algorithm that computes a fetal fraction-based risk score for pregnancy.
Read MoreThis month’s Product News section features products from Qiagen, ELITechGroup Biomedical Systems, and DiaSorin Molecular.
Read MoreA noninvasive prenatal test for zygosity in twin pregnancies enables obstetricians to triage patients and avoid both overtreatment and undertreatment.
Read MoreFor use on Qiagen’s next-generation sequencing system, the cell-free DNA assays will enable access to genetic testing, including prenatal screening, in hospitals and laboratories globally.
Read MoreIllumina has signed a contract with Harvard Pilgrim Health Care to accelerate patient access to next-generation sequencing for noninvasive prenatal testing.
Read MoreThe plastic blood collection tube incorporates a proprietary sample stabilization additive and BD Vacutainer Hemogard technology, and was designed to ensure accurate and reproducible results in molecular diagnostic testing applications using circulating cell-free DNA.
Read MoreThe Panorama noninvasive prenatal test is now validated to screen twin pregnancies for zygosity and chromosomal abnormalities.
Read MoreA large clinical experience study has evaluated the performance of the Panorama noninvasive prenatal test from Natera Inc.
Read MoreThe updated software includes an innovative method for processing samples and is designed for larger batches of 48 samples, versus the current 16 samples.
Read MoreThe test can help physicians identify women at increased risk for premature delivery as early as 19 weeks into the pregnancy.
Read MoreThe test’s associated proprietary software is now cleared for the analysis of data from next-generation sequencing, as well as from qPCR.
Read MoreDelivering accurate results in 5 minutes, the hCG test uses a lateral-flow platform that incorporates an integrated buffer delivery mechanism.
Read More